These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30468974)

  • 21. Bendamustine-rituximab in mantle cell lymphoma.
    Lipsky A; Martin P
    Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.
    Arcari A; Chiappella A; Spina M; Zanlari L; Bernuzzi P; Valenti V; Tani M; Marasca R; Cabras MG; Zambello R; Santagostino A; Ilariucci F; Carli G; Musto P; Savini P; Marino D; Ghio F; Gentile M; Cox MC; Vallisa D
    Leuk Lymphoma; 2016 Aug; 57(8):1823-30. PubMed ID: 26666433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
    Puła B; Budziszewska BK; Rybka J; Gil L; Subocz E; Długosz-Danecka M; Zawirska D; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Kopacz A; Szymczyk A; Czyż J; Lech-Marańda E; Warzocha K; Jamroziak K
    Anticancer Res; 2018 May; 38(5):3025-3030. PubMed ID: 29715135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
    Lavezzi SM; de Jong J; Neyens M; Cramer P; Demirkan F; Fraser G; Bartlett N; Dilhuydy MS; Loscertales J; Avigdor A; Rule S; Samoilova O; Goy A; Ganguly S; Salman M; Howes A; Mahler M; De Nicolao G; Poggesi I
    Pharm Res; 2019 May; 36(7):93. PubMed ID: 31044267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.
    Salar A; Domingo-Domenech E; Panizo C; Nicolás C; Bargay J; Muntañola A; Canales M; Bello JL; Sancho JM; Tomás JF; Rodríguez MJ; Peñalver J; Grande C; Sánchez-Blanco JJ; Palomera L; Arranz R; Conde E; García M; García JF; Caballero D; Montalbán C
    Blood; 2017 Oct; 130(15):1772-1774. PubMed ID: 28801448
    [No Abstract]   [Full Text] [Related]  

  • 26. Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line.
    Hagiwara K; Tokunaga T; Iida H; Nagai H
    Anticancer Res; 2015 Dec; 35(12):6679-84. PubMed ID: 26637884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab.
    Sadeghi N; Li HC
    Ann Hematol; 2018 Apr; 97(4):723-724. PubMed ID: 29285581
    [No Abstract]   [Full Text] [Related]  

  • 28. Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine.
    Hoffman M; Auerbach L
    Br J Haematol; 2000 Jun; 109(4):900-1. PubMed ID: 10970137
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
    Cuneo A; Follows G; Rigolin GM; Piciocchi A; Tedeschi A; Trentin L; Perez AM; Coscia M; Laurenti L; Musuraca G; Farina L; Delgado AR; Orlandi EM; Galieni P; Mauro FR; Visco C; Amendola A; Billio A; Marasca R; Chiarenza A; Meneghini V; Ilariucci F; Marchetti M; Molica S; Re F; Gaidano G; Gonzalez M; Forconi F; Ciolli S; Cortelezzi A; Montillo M; Smolej L; Schuh A; Eyre TA; Kennedy B; Bowles KM; Vignetti M; de la Serna J; Moreno C; Foà R; Ghia P;
    Haematologica; 2018 Jul; 103(7):1209-1217. PubMed ID: 29674504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ibrutinib and rituximab for chronic lymphocytic leukaemia.
    Stirrups R
    Lancet Oncol; 2019 Sep; 20(9):e471. PubMed ID: 31402323
    [No Abstract]   [Full Text] [Related]  

  • 31. Multiply relapsing hairy cell leukemia responsive to repeated courses of rituximab: a case report.
    Buckstein R; Patel H; Chesney A; Reis M; Imrie K
    Hematology; 2006 Aug; 11(4):267-70. PubMed ID: 17178666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
    Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
    Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric monoclonal anti-CD20 antibody (rituximab)--an effective treatment for a patient with relapsing hairy cell leukaemia.
    Hagberg H
    Med Oncol; 1999 Sep; 16(3):221-2. PubMed ID: 10523804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The importance of the tissue microenvironment in hairy cell leukemia.
    Sivina M; Burger JA
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):208-16. PubMed ID: 26614899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax.
    Jain P; Kanagal-Shamanna R; Konoplev S; Zuo Z; Estrov Z
    Am J Hematol; 2018 Dec; 93(12):1568-1569. PubMed ID: 30152528
    [No Abstract]   [Full Text] [Related]  

  • 36. Hairy cell leukaemia-variant: Disease features and treatment.
    Matutes E; Martínez-Trillos A; Campo E
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):253-63. PubMed ID: 26614904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
    Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
    Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-drug combination benefits patients with chronic lymphocytic leukemia.
    Printz C
    Cancer; 2020 Jan; 126(1):13. PubMed ID: 31825544
    [No Abstract]   [Full Text] [Related]  

  • 39. Novel therapeutics in hairy cell leukemia.
    Sarvaria A; Saven A
    Expert Rev Hematol; 2019 Nov; 12(11):983-987. PubMed ID: 31380711
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical and molecular complete remission in a case of variant hairy cell leukemia treated with DHAP followed by high-dose chemotherapy plus rituximab.
    Goldaniga M; Guffanti A; Gianelli U; Magni M; Lambertenghi Deliliers G; Baldini L
    Haematologica; 2004 Nov; 89(11):ECR41. PubMed ID: 15533846
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.